Feature | Breast Imaging | September 17, 2009 | Bernadette M. Greenwood, BSRS, RT(R)(MR)

Breast MRI: All About Timing

Hormone status and menstrual cycle are important considerations in breast MR screening.

Breast MRI images can help identify tumors in dense breast tissue that might be obscured on traditional mammography.

Figure 1 Dense, fibrocystic breast with no well-defined abnormality.

Breast MRI can be used to screen for cancers in women with dense breast tissue.

Fig. 2 Maximum-intensity projection of the breast bilaterally.

Breast MR image showing tumors that were obscured by dense breast issue on a mammogram.

Fig. 3 Prominent right axillary lymph nodes.

 

As breast MRI becomes a more widely accepted modality for breast cancer screening of women at high risk, hormone status and menstrual cycle are important imaging considerations.

“The ideal time for MRI of the breast is approximately between day five and 15 of the menstrual cycle,[5] because the luteal phase of the menstrual cycle with the associated increase in estrogen and progesterone leads to the stroma being edematous with development of the lobules.[1] This leads to increased enhancement during the luteal stage of the menstrual cycle, with the enhancement being maximal seven days before menstruation.[1] Therefore, breast MRI should not be performed during this time, but rather, between days five and 15, long enough after the luteal phase to decrease any residual enhancement.”

Diagnotstic Advantage
There is a diagnostic advantage in using breast MRI in premenopausal women as demonstrated in a case study by William Teh, M.D., consultant radiologist, department of radiology, Northwick Park Hospital, Harrow, and director of screening, North London Breast Screening Service, Edgware Hospital, U.K.6.

On June 15, 2007, a 38-year-old woman with a maternal history of breast cancer and a personal history of infected, left-sided breast cyst presented for a mammogram and ultrasound of right axillary lump. Previous treatment was limited to antibiotics beginning in February 2006. Her mammogram revealed normal dense parenchyma with no interval change from May 2006. Ultrasound showed multiple bilateral breast cysts, prominent right axillary node with cortical thickness of 3.6-mm. US-guided FNA revealed metastic adenocarcinoma.

Eight days later at a follow-up MRI, day 17 of her menstrual cycle, she had multiple breast cysts (Fig.1) and florid, extensive bilateral background enhancement (fig. 2). She also had prominent right axillary nodes(Fig.3). The results showed there was no definite malignant disease. (BIRADS 2)

Her MRI was repeated on July 11, 2007, on day eight of her menstrual cycle. Again, it showed florid background enhancement, but suggestion of discrete 17-mm Type 2 enhancing mass-like lesion in the right lower outer quadrant (Fig. 4, Fig. 5). The doctor performed an MRI-guided vacuum-assisted biopsy with 20 passes utilizing an 11g Mammotome-MR biopsy system. The results revealed a Grade 2 invasive ductal carcinoma with possible vascular invasion. Because this exam was performed during the most favorable time of the menstrual cycle, the results were not impaired by residual hormonal activity, and hence, were more accurate and revealing.

On July 21, 2007, this patient underwent US-guided wire localization for wide local excision and axillary nodal clearance (Level 3). This time results found residual 11-mm Grade 2 invasive carcinoma adjacent to the biopsy cavity. There was an extensive lymphovascular invasion (45 -mm) extending to superior and lateral margins, and ER 8/8 PR 8/8 Her-2 negative 10/13 lymph nodes positive.

The patient then underwent re-excision on August 3, 2007. There was further extensive lymphovascular invasion only, according to tests results. From August through December 2007 she underwent adjuvant chemotherapy (FEC x 3 taxitere x 3). Then from January through February of 2008, radiotherapy was delivered to the breast and supraclavicular fossa. Beginning in March 2008, the patient began tamoxifen therapy.

On January 10, 2009, she had a follow-up MRI of both breasts. The results showed a small discrete Type 2 enhancing 7-mm mass in the right upper inner quadrant. A second look ultrasound was performed on January 28, 2009, which appeared normal. On February 25, 2009, a repeat MRI was performed with normal results, and as of June 19, 2009, this patient appears to remain disease free.

All About Timing
What this case study illustrates is the substantial, diagnostic advantage of timing the breast MRI examination in premenopausal women. Since the breasts are less likely to exhibit residual, hormonal activity between the seventh and 14th days of the menstrual cycle, MRI during this time tends to yield better results. Benign hormonal effect in the breasts can render images somewhat difficult to interpret, particularly in high-risk women with dense, fibrocystic breasts.

Any examination that is difficult to interpret must be repeated or postponed until a time when physical conditions are more favorable and the breast images can be acquired. Therefore, breast MRI examinations on premenopausal women performed between day seven and day 14 of the menstrual cycle are more likely to ensure a more accurate diagnosis and prognosis, as well as a more distinct course of treatment.

 

Related Breast MRI Articles:

From Aviation to Breast Imaging - Development of an Abbreviated Breast MRI Protocol

Implementing Advanced Breast Imaging Technology

Recent Trends and Developments in Contrast Media

Trends in Breast Imaging

 

 

 

References:
1. Sardanelli F, et al. High breast cancer risk Italian trial. Radiology. 2007; 242:698-713.
2. Smith RA. The Evolving role of MRI in the detection and evaluation of breast cancer. NEJM. 2007;356:1362-1364.
3. Shah, Shinil K., BS Shah, Shiwan K., BS Greatrex, Kathleen V., MD. Magnetic Resonance Imaging in Breast Imaging: Quality of Results Timing of the MRI and the Menstrual Cycle.
4. American College of Radiology. American College of Radiology (ACR) Practice Guidelines for the Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast. Reston, VA: American College of Radiology; 2008.
5. Shah, Shinil K., BS Shah, Shiwan K., BS Greatrex, Kathleen V., MD. Magnetic Resonance Imaging in Breast Imaging: Quality of Results Authors and Disclosures. Medscape.com/ viewarticle/518406_4.
6. The case study by William Teh, M.D., Patricia M. MacDonald

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing
iCAD ProFound AI

Image courtesy of iCAD

News | Breast Imaging | June 25, 2019
Use of...